

**Entity Name** 

## **Disclosure of Value Transfers**

## Methodological Note

ESPAÑA
=.

FRESENIUS KABI ESPAÑA, S.A.U.

P	
Legal Basis for Disclosure	Código de Buenas Prácticas de BIOSIM
Reporting Period	2020
Currency of disclosed	All values are disclosed in
values	□ [local currency, if required]
Scope of disclosure	The disclosure covers all interactions with HCPs, HCOs and Patient Organizations related to Biosimilar medicinal products.
Value identification and Recognition	All values disclosed are based on value transfers actually made within the respective category. Such value transfers have been made to a specific recipient and booked in the respective reporting period.
Multi-Year Contracts	Value transfers under multiyear contracts are part of the disclosed data to the extent that actual value transfers have been made in the respective reporting period.
Data disclosed for	<ul> <li>All values are disclosed for</li> <li>Recipients which have been engaged by entity (e.g. EGA)</li> <li>Recipients which have their residence in the country (e.g. BIOSIM)</li> </ul>
VAT and other	All amounts are disclosed without VAT or another taxes.
taxes	
Disclosure location:	https://www.fresenius-kabi.com/es/compania/iniciativa-de- transparencia

Other Remarks	Individualized values for categories related to HCPs.
	Fees paid in connection with research & development activities or market research, have not been disclosed.